Login
$VRDN
$30.76 -$0.11 (0.36%) Live

$VRDN 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

04 Nov 2026 8-K: Results of Operations and Financial Condition

- $24.7 million in Lumvoa™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -

06 Aug 2026 8-K: Results of Operations and Financial Condition

- Lumvoa™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of

29 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

03 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 2, 2026, Viridian Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which holders of the Company’s common stock as of the close of business on April 7, 2026 (the “Record Dat...

28 May 2026 8-K: Termination of a Material Definitive Agreement

On May 27, 2026, Viridian Therapeutics, Inc. (the “Company”) completed a voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to approximately $55.1 million in the aggregate (the...

26 May 2026 8-K: Entry into a Material Definitive Agreement

On May 24, 2026, Viridian Therapeutics, Inc. (the “Company”) entered into a Commercial Manufacturing Services Agreement (the “Agreement”) with WuXi Biologics (Hong Kong) Limited (“WuXi Biologics”) pursuant to which WuXi Biologics will ma...

11 May 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

Introductory. Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) $225,000,000 principal amount of 1.750% Convertible Senior...

05 May 2026 8-K: Regulation FD Disclosure

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,...

05 May 2026 8-K: Results of Operations and Financial Condition

- PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED); organization is launch-ready -

30 Mar 2026 8-K: Regulation FD Disclosure

This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” ...

26 Feb 2026 8-K: Results of Operations and Financial Condition

- PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch -

05 Nov 2025 8-K: Results of Operations and Financial Condition

- Completed a comprehensive set of financing transactions in October 2025, securing access to up to $889 million of potential capital across equity, royalty, and credit -

23 Oct 2025 8-K: Entry into a Material Definitive Agreement

Introductory. Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 11,425,000 shares of its common stock, par...

21 Oct 2025 8-K: Results of Operations and Financial Condition

On October 21, 2025, the Company announced that while it has not finalized its full financial results for the quarter ended September 30, 2025, the Company expects to report that it had approximately $490.9 million of cash, cash equivale...

20 Oct 2025 8-K: Entry into a Material Definitive Agreement

On October 17, 2025, Viridian Therapeutics, Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase and Sale Agreement”) with DRI Healthcare Acquisitions LP (“DRI”), pursuant to which DRI purchased rights to certai...

06 Aug 2025 8-K: Results of Operations and Financial Condition

- Robust execution with multiple upcoming near-term milestones, including planned Biologics License Application (BLA) submission for veligrotug on track in 2H 2025 and expected U.S. commercial launch in 2026 -

30 Jul 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

- Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan -

24 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Continuation of Existing Plan; Successor to and Continuation of Prior Plans. The Plan is intended to serve as a continuation of the Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan, as most recently amended and...

20 May 2025 8-K: Regulation FD Disclosure

THRIVE in Active TED 52-Week Follow-Up Update (May 20, 2025) Exhibit 99.2

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support